The urothelial carcinoma and gastrointestinal cancer treated with anti‐PD‐1 monotherapy have lower TMB ≥ 10 mutation/M than melanoma, lung cancer, and head and neck cancer.28 This evidence concerns the gene PDCD1 and lung carcinoma.